title: Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
abstract: BACKGROUND
  The response to epoetin-alpha treatment is hard to predict in cancer patients receiving chemotherapy.
  
  
  METHODS
  One hundred and seventeen patients were enrolled in this observational study. They had a hemoglobin (Hb) level less than or equal to 10.5 g/dL, were receiving platinum chemotherapy with three cycles pending, and they did not have an iron deficiency or hemolysis. Epoetin-alpha was administered subcutaneously three times a week at a dose of 150 IU/kg. Ninety patients were examined.
  
  
  RESULTS
  Response was defined as an increase in Hb of at least 2 g/dL during the treatment period. The response rate was 63.3%. The following data were compared between responders and nonresponders at the onset of treatment and after 2 and 4 weeks of epoetin therapy: Hb, reticulocytes, serum iron, ferritin, transferrin, transferrin saturation index, and endogenous erythropoietin levels. At baseline, these variables were similar for responders and nonresponders; after 2 weeks, responders showed higher Hb (P = 0.001) and transferrin levels (P = 0.042) and reticulocyte counts (P = 0.003); after 4 weeks, only the Hb level showed a significant difference (P < 0.0005). Changes from baseline in Hb level after 2 and 4 weeks correlated significantly (P < 0.01) with response. The change in Hb level at Week 4 was the best predictor. A change in Hb level of less than 0.5 g/dL was associated with a lack of response (predictive power, 71%); a change in Hb greater than or equal to 0.5 g/dL was associated with response (predictive power, 89%).
  
  
  CONCLUSIONS
  Response to epoetin-alpha treatment in cancer patients receiving platinum chemotherapy can be predicted from changes in Hb level after 4 weeks of therapy.
authors.affiliation: Hospital La Paz, Servicio de Oncología Médica, Madrid, Spain. oncopaz@ene.es
authors.forename: Manolo
authors.initials: M
authors.lastname: González-Barón
authors.forename: Amdio
authors.initials: A
authors.lastname: Ordóñez
authors.forename: Rosa
authors.initials: R
authors.lastname: Franquesa
authors.forename: Manuel
authors.initials: M
authors.lastname: Constenla
authors.forename: Joaquin
authors.initials: J
authors.lastname: Montalar
authors.forename: Frederic
authors.initials: F
authors.lastname: Gili
authors.forename: Carlos
authors.initials: C
authors.lastname: Camps
authors.forename: José Felix
authors.initials: JF
authors.lastname: Sancho
authors.forename: Pedro
authors.initials: P
authors.lastname: Pérez-Cachot
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000009:adverse effects* / Q000627:therapeutic use; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006397:Hematinics / Q000008:administration & dosage / Q000494:pharmacology*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D002945:Cisplatin